Mehmet Akif Sargin

Suggest Changes
Learn More
BACKGROUND Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for once-weekly subcutaneous administration, in development for treatment of type 2 diabetes. We assessed the(More)